A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
Clinical Focus
Practice Locations
Education
Dartmouth-Hitchcock Medical Center
ResidencyDartmouth-Hitchcock Medical Center
Medical SchoolUniversity of Kentucky College of Medicine
FellowshipWashington University in St. Louis
Board Certifications
American Board of Internal Medicine
Medical OncologyAmerican Board of Internal Medicine
Internal MedicineAmerican Board of Internal Medicine
Hospital Affiliations
- Baptist Health Medical Group
- Baptist Health Lexington
- Baptist Health Richmond
Philosophy of Care
Research
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
About Amy M Schell
Insurance
Our providers accept many insurance plans. Check the Baptist Health insurance policy to make sure yours is one of them.